<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544698</url>
  </required_header>
  <id_info>
    <org_study_id>cycdc2015-2</org_study_id>
    <nct_id>NCT02544698</nct_id>
  </id_info>
  <brief_title>Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chaoyang District Centre for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chaoyang District Centre for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety of Pneumococcal 13-valent Conjugate Vaccine in Healthy People
      Aged 2 Months and Older.120 Subjects will be equally divided into 4 groups,including 18 years
      and older,2-5 years old, 2 months old and 3 months old. Subjects aged 18 years and 2-5 years
      old will receive one dose of PCV13 vaccine,while subjects aged 2 and 3 months will receive 3
      doses of PCV13 vaccine,injected at 2, 4, 6 months or 3、4、5 months respectively.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the rate of adverse reactions of pneumococcal 13-valent conjugate vaccine</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pneumococcal 13-valent Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>One dose of PCV13a vaccine in aged 18 years and older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of PCV13a vaccine will be given in aged 18 years and older</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One dose of PCV13a vaccine in aged 2-5 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of PCV13a vaccine will be given in aged 2-5 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One dose of PCV13 vaccine will be given at 2, 4, 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One dose of PCV13 vaccine will be given at 3、4、5 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One dose of PCV13a vaccine</intervention_name>
    <arm_group_label>One dose of PCV13a vaccine in aged 18 years and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One dose of PCV13a vaccine</intervention_name>
    <arm_group_label>One dose of PCV13a vaccine in aged 2-5 years old</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>three doses of PCV13a vaccine</intervention_name>
    <arm_group_label>One dose of PCV13 vaccine will be given at 2, 4, 6 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>three doses of PCV13a vaccine</intervention_name>
    <arm_group_label>One dose of PCV13 vaccine will be given at 3、4、5 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy babies with health conditions confirmed according to medical history, medical
             examination and judgment of researchers;

          2. Satisfy the age requirements of the clinical trial.(children from 2 months to 5 years
             old and adults over the age of 18);

          3. Parents or guardians of the subjects must provide informed consent forms with
             personally signature and date;

          4. Parents or guardians of the subjects have been informed of all aspects of the
             research;

          5. Subjects or guardians can obey the requirements of the clinical research;

          6. No pneumococcal vaccine inoculation history, no other preventive vaccination within 7
             days;

          7. Axillary temperature below 37℃

        Exclusion Criteria:

          1. People with pneumococcal vaccine inoculation history, no matter experimentally or
             already on the market;

          2. People has allergic reaction to any drugs, vaccine or vaccine-related components
             previously;

          3. People has allergic reaction to 13vPnC, 7vPnC or other complexes associated with the
             drug, known or suspected;

          4. People has hemorrhagic physical constitution or diseases that prolong bleeding time,
             intramuscular injection taboo;

          5. People has immune deficiency or immune function inhibition, known or suspected;

          6. People has irritability, convulsions, epilepsy, brain diseases and mental history or
             family history;

          7. People has culture-confirmed invasive diseases caused by streptococcus pneumoniae
             history;

          8. People has serious congenital malformations or serious chronic diseases that are
             known, people with congenital deformities, stunted or has a clinical diagnosis of
             serious chronic diseases (such as Down syndrome, diabetes, sickle cell anemia or nerve
             disorders, Guillain-Barre syndrome);

          9. People suffers from these diseases: respiratory diseases, acute or chronic active
             stage of infection, severe cardiovascular disease, kidney and liver diseases,
             malignant tumors, skin diseases, babies with HIV infected mothers(inspection report is
             available);

         10. People with vaccination-related contraindications that other researchers believe;

         11. People take part in other clinical trials while taking part in this clinical trial or
             28 days before this clinical trial. People who participate in purely observational
             studies are acceptable;

         12. People received blood products or intravenous immunoglobulin. People who was
             inoculated Hepatitis B immunoglobulin can be acceptable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

